Amount of suitable people: CDEC mentioned the uncertainty in the amount of sufferers with moderately critical to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some sufferers who're categorized as possessing delicate or reasonable ailment could have a significant bleed